Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:00am, Thursday, 02'nd Jan 2025
BRIDGEWATER, N.J. , Jan. 2, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
5 Biotech Breakthrough Stocks to Watch in 2025
10:40am, Monday, 23'rd Dec 2024
After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointmen
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Friday, 06'th Dec 2024
BRIDGEWATER, N.J. , Dec. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
Insmed To Present at December 2024 Investor Conferences
08:00am, Monday, 02'nd Dec 2024
BRIDGEWATER, N.J. , Dec. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data
02:09pm, Wednesday, 20'th Nov 2024
Insmed Incorporated's ARIKAYCE, approved for MAC lung disease, achieved strong revenue growth in Q3 of 2024 and potential for expanded FDA approval, boosting its market opportunity. Brensocatib's NDA
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Thursday, 07'th Nov 2024
BRIDGEWATER, N.J. , Nov. 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
Insmed To Present at November 2024 Investor Conferences
08:00am, Wednesday, 06'th Nov 2024
BRIDGEWATER, N.J. , Nov. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
Insmed (INSM) Reliance on International Sales: What Investors Need to Know
10:22am, Monday, 04'th Nov 2024
Review Insmed's (INSM) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates
09:46am, Friday, 01'st Nov 2024
INSM posts wider-than-expected Q3 loss. The company plans to meet the FDA before 2024-end to discuss the possibility of an accelerated approval to expand Arikayce's label.
Insmed Incorporated (INSM) Q3 2024 Earnings Call Transcript
02:31pm, Thursday, 31'st Oct 2024
Insmed Incorporated (NASDAQ:INSM ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Bryan Dunn – Head of Investor Relations Will Lewis – Chair and Chief Executive
Insmed (INSM) Reports Q3 Earnings: What Key Metrics Have to Say
11:01am, Thursday, 31'st Oct 2024
While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compar
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
09:16am, Thursday, 31'st Oct 2024
Insmed (INSM) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to loss of $1.10 per share a year ago.
Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update
07:00am, Thursday, 31'st Oct 2024
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023— —NDA Submission for Bren
Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
10:20am, Wednesday, 30'th Oct 2024
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qua
Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List
04:05pm, Thursday, 24'th Oct 2024
—Insmed Leads Science Top Employers List for Fourth Year in a Row— BRIDGEWATER, N.J. , Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical comp
